Evidence map›Paper›PMID 39953460›Full record

ArticleBMC cancer2025

Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Zhang Xinjing, Gong Lei, Li Xinbao, Ji Zhonghe, Yang Zhiran, Gao Chao, Zhang Kai, Yan Lijun, Yan Guojun, Yu Junhui and 2 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhang Xinjing *Department of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Gong Lei *Department of hepatobiliary surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Li XinbaoDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Ji ZhongheDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Yang ZhiranDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Gao ChaoDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Zhang KaiDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Yan LijunDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Yan GuojunDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Yu JunhuiDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
Zhang YanbinDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China.
An SonglinDepartment of peritoneal surface surgical oncology, Beijing Shijitan Hospital, Capital Medical University, Tieyi road 10th, Haidian district, Beijing, 100038, China. zi1ran588@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for selected patients. The purpose of this study was to thoroughly examine the impact of the combined treatment and the prognostic variables, particularly the neutrophil-to-lymphocyte ratio (NLR).

methodsCharacteristics of MPM patients who underwent CRS combined HIPEC treatment, followed by adjuvant chemotherapy were retrospectively collected. The univariable analysis was performed to identify the decisive influential factor. Using Kaplan-Meier analysis, the cumulative probability of survival was determined. Using Univariate Cox analysis, the prognostic factors-particularly NLR-and its correlation with survival were assessed. In the multivariate Cox proportional hazards model, predictive factors that demonstrated significance in univariate analysis were used. The degree of connection between predictors and survival was evaluated through the use of hazard ratios (HRs) and 95% confidence intervals (95% CIs).

resultsA total of 64 patients were enrolled in this study. The 1, 3, 5 years survival rates were 70.3%, 65.6%, 59.4%, respectively. According to multivariate Cox analysis, patients' survival was found to be substantially associated with post-operative NLR (HR 0.180, 0.067-0.531), Ki-67 (HR 0.184, 0.024-0.817), post-operative neutrophil count (HR 0.228, 0.075-0.696), and bidirectional pathological type (HR, 0.375, 0.146-0.964).

conclusionsNLR is associated with the patients' prognosis after CRS combined HIPEC treatment.

Indexed as

Cytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyLung NeoplasmsLymphocytesMesotheliomaNeutrophilsPeritoneal NeoplasmsAdultAgedCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMesothelioma, MalignantMiddle AgedCytoreductive SurgeryHyperthermic Intraperitoneal ChemotherapyMalignant Peritoneal MesotheliomaNeutrophil-to-Lymphocyte RatioPrognosis

Identifiers

PMID39953460
PMCPMC11829406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.